The controversy over pricing of EpiPens, and, relatedly, the $2 million a year that Mylan spends on Washington lobbying, is the topic of my column this week. Please check it out at the New York Post (here), New York Sun (here), Reason (here), and Newsmax (here).
EpiPen-Maker Mylan's Lobbying
https://www.futureofcapitalism.com/2016/08/epipen-maker-mylan-lobbying
by Editor | Related Topics: Compensation, Health Care, Politics, Revolving Door, Senator Schumer receive the latest by email: subscribe to the free futureofcapitalism.com mailing list
